Program
Anti-PSMA/Anti-CD3 Dual-masked T-cell Engager JANX014
Its studies are mostly in Prostatic Neoplasms, led by Janux Therapeutics.
Furthest: phase 1, since Apr 16, 20261 company-led study, 1 open or runningNext primary completion: May 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Janux Therapeutics | 11 open or running | phase 1since Apr 16, 2026 | Apr 16, 2026 | May 2028phase 1 · NCT07545811 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 16, 2026First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT07545811 · 43 planned · United States
Ahead
- May 2028Primary completion: phase 1 study in Prostatic NeoplasmsNCT07545811
TargetBeta
“A tumor-activated, double-masked T-cell engager (TCE) directed against the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA) and the CD3 antigen found on T-lymphocytes, ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| olsutamigrule | Regeneron Pharmaceuticals | phase 2 | 2 |
| Anti-PSMA/Anti-CD3 T-cell Engager GSK5458514rule | GlaxoSmithKline | phase 2 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07545811Prostatic Neoplasms · United States | 1 | Recruiting | May 2028 | 43 |
How it is read
Names in the registry
- “JANX014”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.